Scientists Ejected From ADA Conference Over Criticism Of Trump’s Research Crackdown

Scientists ousted from major diabetes conference for distributing editorial criticizing Trump administration’s research policies

Five leading diabetes researchers were forcibly removed from the annual meeting of the American Diabetes Association (ADA) on June 5, 2026, after distributing copies of a peer-reviewed editorial sharply critical of the Trump administration’s ongoing restrictions on scientific research. The incident, confirmed by multiple sources, marks a dramatic escalation in tensions between federal health officials and the medical research community.

The researchers—Steven Kahn (University of Washington, editor-in-chief of Diabetes Care), Desmond Schatz (University of Florida, former ADA president), Aaron Kelly (University of Minnesota), Justin Ryder (Northwestern University), and Irl Hirsch (University of Washington)—were distributing reprints of an editorial published in Diabetes Care on April 29, 2026. The editorial called on scientists to resist what it described as “systematic attacks” on evidence-based research, including funding cuts and political interference in federal agencies like the National Institutes of Health (NIH).

The confrontation occurred outside a session where NIH Director Jay Bhattacharya was scheduled to speak. Bhattacharya canceled his appearance, and another NIH official delivered his remarks instead. According to Aaron Kelly, who spoke to MedPage Today, conference security physically removed the researchers, confiscated their badges, and barred them from further attendance.

“They physically grabbed us, forced us out of the conference center, and now are telling us we can no longer attend this meeting,” Kelly said. “They’re taking our lanyards. It really has come to this in America. Censorship is real. America needs to stand up. Scientists, stand up. Physicians, stand up.”

The ADA has not publicly commented on the incident, but the removal of the researchers—all of whom hold prominent roles in diabetes research—raises questions about the boundaries of academic freedom at major medical conferences. The editorial they distributed had already drawn attention for its blunt language, with one passage describing the Trump administration’s policies as “a direct threat to public health” by undermining peer-reviewed science.

Why This Matters in the Broader Tech and Science Policy Landscape

The incident reflects a growing divide between federal health agencies and the scientific community over research funding, regulatory oversight, and the role of political influence in medical decision-making. While the Trump administration has defended its policies as efforts to streamline bureaucracy, critics argue they have led to reduced transparency in NIH grant reviews, delays in emergency response funding, and increased self-censorship among researchers fearing retaliation.

This is not the first time scientists have faced consequences for publicly challenging administration policies. In 2020, a group of epidemiologists was barred from testifying before Congress after submitting a report critical of the NIH’s handling of COVID-19 research funding. More recently, climate scientists at federal agencies reported being pressured to alter public statements to align with administration priorities.

The ADA conference incident also highlights the real-world impact on patient care. Diabetes research relies heavily on NIH funding, and restrictions on grants or data-sharing protocols could delay breakthroughs in treatments for complications like neuropathy, cardiovascular disease, and type 1 diabetes—a condition affecting over 37 million Americans, according to the CDC.

What Comes Next?

The researchers plan to file a formal complaint with the ADA, demanding an explanation for their removal and a review of conference policies on free speech. Legal experts suggest they may also pursue claims under the First Amendment, given the conference’s status as a public forum for medical professionals.

Meanwhile, the NIH has not responded to requests for comment on Bhattacharya’s canceled appearance or the broader context of the editorial’s publication. The Trump administration has not issued a statement on the matter, though White House officials have previously dismissed concerns about scientific censorship as “baseless attacks.”

For the tech and health policy communities, the incident serves as a warning: as AI-driven medical research and algorithmic drug discovery grow in influence, conflicts between political agendas and evidence-based science could reshape how federal agencies fund—and restrict—innovation.

Sources:

• MedPage Today (June 5, 2026) – Reporting on the ADA conference incident and quotes from Aaron Kelly.
• Diabetes Care (April 29, 2026) – Editorial titled “Scientific Integrity Under Attack: A Call to Action.”
• American Diabetes Association – Conference program and NIH session details.
• National Institutes of Health – Public records on Bhattacharya’s scheduled appearance.